Update shared on10 Aug 2025
The decrease in Iovance Biotherapeutics' consensus price target is primarily driven by a reduction in expected annual revenue growth from 49.7% to 45.5%, resulting in a lowered fair value estimate from $10.00 to $9.10.
What's in the News
- Five-year results from the Phase 2 C-144-01 trial showed Amtagvi (lifileucel) produced a median OS of 13.9 months and a 31.4% objective response rate in advanced melanoma patients; 19.7% survived at five years with durable responses and no new safety concerns.
- The Journal of Clinical Oncology published the final analysis of the C-144-01 trial, supporting Amtagvi’s benefit in advanced melanoma, but highlighted regulatory and operational risks for future commercialization and manufacturing expansion.
- A real-world study demonstrated the clinical benefit of Amtagvi in patients with advanced melanoma post-immune checkpoint inhibitor therapy; however, market, pricing, reimbursement, and manufacturing challenges persist, alongside ongoing regulatory risk.
- Iovance slashed its 2025 revenue guidance from $450–$475 million to $250–$300 million citing slower-than-expected uptake of Amtagvi; this triggered a securities class action lawsuit alleging misleading statements about sales challenges and operational issues, and caused a significant share price decline.
- Significant index rebalancing occurred: Iovance was dropped from multiple Russell "Growth" indexes and added to "Value" indexes, reflecting a shift in market perception; CFO Jean-Marc Bellemin resigned and was succeeded by Corleen Roche, an experienced biotech financial executive.
Valuation Changes
Summary of Valuation Changes for Iovance Biotherapeutics
- The Consensus Analyst Price Target has fallen from $10.00 to $9.10.
- The Consensus Revenue Growth forecasts for Iovance Biotherapeutics has fallen from 49.7% per annum to 45.5% per annum.
- The Future P/E for Iovance Biotherapeutics has fallen slightly from 49.37x to 47.25x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.